Study of Lupus Low Disease Activity State LLDAS in Adults with Systemic Lupus Erythematosus in the Asia Pacific Region

What this Trial Is About

Researchers are evaluating the Lupus Low Disease Activity State LLDAS in patients with Systemic Lupus Erythematosus SLE, a complex autoimmune disease affecting multiple organs and causing serious health problems. The study aims to see if achieving LLDAS is linked to better outcomes, including less organ damage, as traditional remission is rare and difficult to measure in lupus patients. The study is international and multi-center, led by the Asia Pacific Lupus Collaboration and sponsored by Monash University. Patients with SLE will be followed for approximately five years. During this time, researchers will collect regular data on disease activity and treatment to assess whether patients meet the LLDAS criteria. Annual assessments will also record lupus-related organ damage using the SLICC-ACR Damage Index and quality of life using the Short Form 36 version 2. At the end of the study, the researchers will evaluate if sustained LLDAS protects against organ damage. Participants will have their clinical and treatment data monitored regularly over several years. The study will measure outcomes including organ damage progression, quality of life, and mortality. These long-term assessments will help determine whether LLDAS is a useful target in managing lupus. The total participation time is about five to ten years, allowing detailed tracking of disease impact and patient well-being.

Validation of the Lupus Low Disease Activity State (LLDAS) in the Asia Pacific Region